Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma Journal Article


Authors: Beroukhim, R.; Getz, G.; Nghiemphu, L.; Barretina, J.; Hsueh, T.; Linhart, D.; Vivanco, I.; Lee, J. C.; Huang, J. H.; Alexander, S.; Du, J.; Kau, T.; Thomas, R. K.; Shah, K.; Soto, H.; Perner, S.; Prensner, J.; Debiasi, R. M.; Demichelis, F.; Hatton, C.; Rubin, M. A.; Garraway, L. A.; Nelson, S. F.; Liau, L.; Mischel, P. S.; Cloughesy, T. F.; Meyerson, M.; Golub, T. A.; Lander, E. S.; Mellinghoff, I. K.; Sellers, W. R.
Article Title: Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Abstract: Comprehensive knowledge of the genomic alterations that underlie cancer is a critical foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to analyze cancer genomes are underway, but the analysis is hampered by the lack of a statistical framework to distinguish meaningful events from random background aberrations. Here we describe a systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer. We use it to study chromosomal aberrations in 141 gliomas and compare the results with two prior studies. Traditional methods highlight hundreds of altered regions with little concordance between studies. The new approach reveals a highly concordant picture involving ≈35 significant events, including 16-18 broad events near chromosome-arm size and 16-21 focal events. Approximately half of these events correspond to known cancer-related genes, only some of which have been previously tied to glioma. We also show that superimposed broad and focal events may have different biological consequences. Specifically, gliomas with broad amplification of chromosome 7 have properties different from those with overlapping focal EGFR amplification: the broad events act in part through effects on MET and its ligand HGF and correlate with MET dependence in vitro. Our results support the feasibility and utility of systematic characterization of the cancer genome. © 2007 by The National Academy of Sciences of the USA.
Keywords: controlled study; protein phosphorylation; human cell; major clinical study; single nucleotide polymorphism; polymorphism, single nucleotide; brain tumor; glioma; methodology; epidermal growth factor receptor; cell line, tumor; protein p53; scatter factor; chromosome aberration; data interpretation, statistical; probability; glioblastoma; western blotting; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; chromosome aberrations; bioinformatics; comparative genomic hybridization; genomic dna; scatter factor receptor; chromosome 7; copynumber alterations; single-nucleotide polymorphism arrays
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 104
Issue: 50
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 2007-12-11
Start Page: 20007
End Page: 20012
Language: English
DOI: 10.1073/pnas.0710052104
PUBMED: 18077431
PROVIDER: scopus
PMCID: PMC2148413
DOI/URL:
Notes: --- - "Cited By (since 1996): 168" - "Export Date: 17 November 2011" - "CODEN: PNASA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors